| Literature DB >> 32508447 |
Suchitra Rajesh Gosavi1, Amruta Appasaheb Torkadi1.
Abstract
CONTEXT: Early detection of oral squamous cell carcinoma (OSCC) and oral submucous fibrosis (OSMF) transforming into malignancy can drastically improve the treatment outcomes and prognosis. Carcinoma development is an intricate complex mechanism and the multifactorial causation makes it more difficult to find specific prognostic and therapeutic biomarkers. Thus, the development of newer diagnostic and predictive approaches that are less invasive, economical and amenable to repeated sampling is imperative. Serum C-reactive protein (CRP) serves a useful marker for prognosis and monitoring of oral potentially malignant disorders (OPMDs) including OSMF as well as OSCC. Secreted by hepatocyte as an acute inflammatory marker, various studies have shown association between serum CRP and presence of OPMDs, as well as with presence and prognosis of OSCC. AIMS: The aim of this study was to measure and compare serum CRP levels in patients with OSMF and OSCC as compared to healthy individuals and to establish baseline data for serum CRP levels in patients with OSMF and OSCC. SETTINGS ANDEntities:
Keywords: C-reactive protein; oral potentially malignant disorder; oral squamous cell carcinoma; oral submucous fibrosis
Year: 2020 PMID: 32508447 PMCID: PMC7269289 DOI: 10.4103/jomfp.JOMFP_317_19
Source DB: PubMed Journal: J Oral Maxillofac Pathol ISSN: 0973-029X
Comparison of mean serum CRP values in Group I and Group II subjects
| Group | Number | Mean CRP | Std. deviation | |
|---|---|---|---|---|
| Group I | 50 | 2.20 | 1.74 | 0.07 |
| Group II | 50 | 5.40 | 4.79 |
Comparison of mean serum CRP values in Group II subjects based on interincisal opening (IIO)
| Group | Number | Mean CRP | Std. deviation | ||
|---|---|---|---|---|---|
| Group IIA (IIO >35 mm ) | 2 | 1.35 | 1.52 | 0.16 | Group IIA=Group |
| Group IIB IIO=26 to 35 mm | 16 | 7.34 | 6.51 | IIB=Group | |
| Group IIC IIO=16 to 25 mm | 22 | 4.37 | 3.71 | IIC=Group IID | |
| Group IID IIO <15 mm, without any other premalignant lesion | 10 | 5.36 | 2.97 | ||
| Group IIE IIO <15 mm , with presence of premalignant lesion | 0 | 0 | 0 |
Comparison of mean serum CRP values in Group I and Group III subjects
| Group | Number | Mean CRP | Std. deviation | |
|---|---|---|---|---|
| Group I | 50 | 2.20 | 1.74 | <0.001 |
| Group III | 50 | 12.17 | 11.38 |
Comparison of mean serum CRP values in Group III subjects based on primary tumor size (T)
| Size | Mean CRP | Std. deviation | ||
|---|---|---|---|---|
| T1 (2 cm or less, | 6.03 | 4.51 | 0.004 | (T1=T2) |
| T2 (2 cm-4 cm, | 8.42 | 2.09 | < T3 | |
| T3 (size>4 cm, | 17.70 | 14.68 |
Comparison of mean serum CRP values in Group I, Group II and Group III subjects
| Group | Number | Mean CRP | Std. deviation | Post hoc test | |
|---|---|---|---|---|---|
| Group I | 50 | 2.20 | 1.74 | <0.001 | Group III |
| Group II | 50 | 5.40 | 4.79 | ||
| Group III | 50 | 12.17 | 11.38 | ||
| Total | 150 | 6.59 | 8.28 |